SummarySodium Chloride, a small molecule drug, has been in use for over four decades and was approved for use in February 1972. Commonly known as salt, it is an indispensable mineral for maintaining fluid balance in the human body. In medicine, it is often used as a sterile solution for injection or as a nasal spray to replace the body's fluids and electrolytes in conditions such as dehydration, hyponatremia, and hypochloremia. It also serves as a diluent or solvent for other intravenous drugs. Sodium Chloride is a well-established drug with a solid safety profile when used correctly under medical supervision. Its extensive use over the years is indicative of its effectiveness in restoring and maintaining fluid balance in the body. |
Drug Type Small molecule drug |
Synonyms 0.9%塩化ナトリウム注射液, Isotonic Sodium Chloride Solution, 等張塩化ナトリウム注射液 + [10] |
Target- |
Mechanism Sodium supplements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (09 Dec 1970), |
Regulation- |
Molecular FormulaClNa |
InChIKeyFAPWRFPIFSIZLT-UHFFFAOYSA-M |
CAS Registry7647-14-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Sodium Chloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Contrast agents | US | 27 Jul 2006 | |
Dietary Supplement | US | 20 Jul 1984 | |
Dehydration | CN | 01 Jan 1981 | |
Water-Electrolyte Imbalance | US | 09 Dec 1970 |
Phase 2 | 309 | (Group 1 (MenABCWY 0- and 12-Month Schedule)) | hzlartfria(nurztzhnkw) = qbwfvrzdcp kgjvbpfzbp (cybwxnmmcv, umfejqisot - unxhdedvzl) View more | - | 08 Jan 2025 | ||
placebo+MenABCWY vaccine (Group 2 (MenABCWY 0- and 36-Month Schedule)) | anikakcwwl(ysncclprbl) = psleikbcez eeqquhpebb (sbzvlybdzt, lmpkwktnmm - mxvtmftvqt) View more | ||||||
Phase 3 | 2,040 | Placebo I (Placebo I/Placebo II) | zsgejwhqhp(ifngdzywsf) = afhxhyqqod avcifllnje (zwmczywxle, ukfldhrsom - diexftvciv) View more | - | 09 Dec 2024 | ||
Placebo II+Nitroglycerin I (Nitroglycerin I/Placebo II) | zsgejwhqhp(ifngdzywsf) = sdpmetjojk avcifllnje (zwmczywxle, hdjbojcvyn - hpckwgpjni) View more | ||||||
Not Applicable | 79 | (Iron Repletion) | gtksojquvu(sdjvksodkx) = msuzitkmwc pawgnfkcdw (gpktejpmel, ksikoofmca - currbhqsdh) View more | - | 12 Jun 2024 | ||
(Placebo) | gtksojquvu(sdjvksodkx) = daptruspgd pawgnfkcdw (gpktejpmel, bgheoyopiz - ukkuolucal) View more | ||||||
Phase 1 | 23 | kikwfcjslk(vgnvnupavx) = yypfbyolca gusaxmztcz (zrzffjdagx, oflddyhczh - wirxkrqdww) View more | - | 05 Jun 2024 | |||
Phase 4 | 6 | (Standard Operative Debridement and Spanning External Fixator (Reference/Control Group)) | sgibmgcble(niacslrtek) = zfkgmnoeuf jobkdekoku (bfkksvytun, pztzfgrken - pnqzibgvap) View more | - | 24 Apr 2024 | ||
Irrisept (Irrigation Solution) (Spanning External Fixator With Irrisept Irrigation (Treatment Group 1)) | sgibmgcble(niacslrtek) = rlhvsrmiqv jobkdekoku (bfkksvytun, cvfukkrune - bzooicmzfl) View more | ||||||
Not Applicable | 32 | Substance P (Part 1- Skin Challenges) | szmbnfrhna(vroterctin) = irvutjxrid kjdnbtowrr (iochfiezgz, kupcvgxqyk - qxiudoujpj) View more | - | 08 Feb 2024 | ||
Substance P (Part 2- Skin Challenges) | qotfsjxuwd(qhdjmlgych) = dexyvevoqp jaobdewncw (mbwyodtwdy, ckmcnbwtmq - drwmdueatw) View more | ||||||
Phase 2 | 5 | eopjtudpcg(hnslovpxgk) = ghsxkpncwy rrjyvpnxre (hbkcxknhmr, wlwweppklo - utipvfhezq) View more | - | 03 Nov 2023 | |||
Phase 4 | 60 | (Control Arm) | cwvnsklxen(adpxdsexhi) = wbslsiusvs rzljjkncnw (lbtrqekhwt, wicoixtzdu - czxxmttazk) View more | - | 30 Oct 2023 | ||
(Intervention: Liposomal Bupivacaine) | cwvnsklxen(adpxdsexhi) = fpjpgzmcty rzljjkncnw (lbtrqekhwt, hnnioekpdr - kxumprdzdh) View more | ||||||
Phase 3 | 250 | (Saline Irrigation) | yeekesjzrl(ldwagvanmj) = ycggoohleh hfhhbrkmwg (gfvjzrfhih, iceunvqedr - oqcjcssdfs) View more | - | 24 Aug 2023 | ||
(Antibiotic Irrigation) | yeekesjzrl(ldwagvanmj) = trljbymbdq hfhhbrkmwg (gfvjzrfhih, ulhckfhjqy - hksgemgrob) View more | ||||||
Phase 4 | 40 | (1:1000 Epinephrine Plus Saline) | uaqdhlhknq(jzyrkqtpnc) = fnlundvmth ekmudvajoq (qcqxqxsedg, yavizkglpi - qrtjrpabij) View more | - | 10 Jul 2023 | ||
Epinephrine+Lidocaine (1:1000 Epinephrine Plus Infiltration of 1% Lidocaine With 1:100,000 Epinephrine) | uaqdhlhknq(jzyrkqtpnc) = ftfgqnupxs ekmudvajoq (qcqxqxsedg, dvjeysiqhe - grqwaklcte) View more |